Recent developments in critical genes in the molecular biology of breast cancer

Asian Journal of Surgery

Volumn 28, Issue 1, 2005, Pages 71-75

  Sunpaweravong, Somkiat ^a   Sunpaweravong, Patrapim ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

BRCA1; BRCA2; Breast cancer; HER2; p53

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PROTEIN P53; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER GENETICS; CANCER INCIDENCE; CARDIOTOXICITY; CATARACT; CHROMOSOME 17; ENDOMETRIUM CANCER; GENE; GENE MUTATION; GENE THERAPY; HER2 GENE; HUMAN; MASTECTOMY; MOLECULAR BIOLOGY; MOLECULAR GENETICS; ONCOGENE; REVIEW; SYSTEMATIC REVIEW; TUMOR SUPPRESSOR GENE; VENOUS THROMBOEMBOLISM;

EID: 14644439858     PISSN: 10159584     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1015-9584(09)60265-7     Document Type: Review

References (46)

1. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990;250:1684-9.
2. Wooster R, Neuhausen SL, Mangion J, et al. Localization of abreast cancer susceptibility gene, BRCA2, to chromosome 13q 12-13. Science 1994;265:2088-90.
3. Nagahata T, Kosaka N, Shimizu M, et al. Molecular diagnosis for breast cancer. Japan Medical Association Journal 2002;45:265-70.
4. Berry DA, Parmigiani G, Sanchez J, et al. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997;89:227-38.
5. Couch FJ, DeShano ML, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997;336:1409-15.
6. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2 Cancer Genetics Studies Consortium. JAMA 1997;277:997-1003.
7. Armstrong KA, Eisen A, Weber B. Assessing the risk of breast cancer. N Engl J Med 2000;342:5 64-71.
8. Daly MB, Angelos P, Bryant E, et al. The NCCN 2002 genetic/familial high-risk assessment: clinical practice guidelines in oncology, version 1.2003. Available at www.nccn.com.
9. Warner EPD, Shumak RS, Catzavelos GC, et al. Comparison of breast magnetic resonance imaging, mammography, and ultra-sound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001;19:3524-31.
10. Kuhl CK, Schmutzler RK, Leutner CC, et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of abreast cancer susceptibility gene: preliminary results. Radiology 2000;215:267-79.
11. Kriege M, Brekelmens CTM, Boetes C, et al. MRI screening for breast cancer in women with high familial and genetic risk: first results of the Dutch MRI Screening Study (MRISC). Proc Am Soc Clin Oncol 2003;22:2.
12. Narod SA, Brunet JS, Ghadiirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000;356:1876-81.
13. Robson ME. Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer. Cancer Control 2002;9:457-65.
14. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. JAMA 2001;286:2251-61.
15. Pichart G, Bolliger B, Buser K, et al. Evidence-based management options for women at increased breast/ovarian cancer risk. Ann Oncol 2003;14:9-19.
16. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77-84.
17. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001;93:1633-7.
18. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 and BRCA2 mutation. N Engl J Med 2002;346:1609-15.
19. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 and BRCA2 mutation. N Engl J Med 2002;346:1616-22.
20. Horton J. Trastuzumab use in breast cancer: clinical issues. Cancer Control 2002;9:499-507.
21. Salmon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
22. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: the influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994;73:2359-65.
23. Bianco AR, De Laurentiis M, Carlomagno C, et al. HER2 overexpression predicts adjuvant tamoxifen (TAM) failure for early breast cancer (EBC): complete data at 20 yr of the Naples GUN randomized trial. Proc Am Soc Clin Oncol 2000;19:289a.
24. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2. N Engl J Med 2001;344:783-92.
25. Ross JS, Fletcher JA, Linette GP, et al. The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003;8:307-25.
26. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7.
27. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002;95:1592-600.
28. Ewer MS, Vooletich M, Valero V, et al. Trastuzumab (Herceptin) cardiotoxicity: clinical course and cardiac biopsy correlations. Proc Am Soc Clin Oncol 2002;21:489.
29. DeLeo AB, Jay G, Appella E, et al. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci USA 1979;76:2420-4.
30. Beroud C, Soussi T. p53 gene mutation: software and database. Nucleic Acids Res 1998;26:200-4.
31. Beroud C, Soussi T. The UMD p53 database: new mutations and analysis tools. Hum Mutat 2003;21:176-81.
32. Oliver M, Eeles R, Hollstein M, et al. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002;19:607-14.
33. Soussi T, Dehouche K, Beroud C. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat 2000;15:105-13.
34. Soussi T, Beroud C. Assessing TP53 status in human tumors to evaluate clinical outcome. Nat Rev Cancer 2001;1:233-40.
35. Borresen AL. TP53 and breast cancer. Hum Mutat 2003;21:292-300.
36. Berns EM, Foekens JA, Vossen R, et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 2000;60:2155-62.
37. Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 1999;80:1968-73.
38. Aas T, Borresen AL, Geisler S, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-4.
39. Geisler S, Lonning PE, Aas T, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001;61:2505-12.
40. Berns EM, Foekens JA, Vossen R, et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 2000;60:2155-62.
41. Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neo-adjuvant treatment in breast cancer patients. Clin Cancer Res 2000;6:50-6.
42. Nemunaitis J, O'Brien J. Head and neck cancer: gene therapy approaches. Part II: gene delivered. Expert Opin Biol Ther 2002;3:311-24.
43. Swisher SG, Roth JA. Clinical update of Ad-p53 gene therapy for lung cancer. Surg Oncol Clin North Am 2002;3:521-35.
44. Buller RE, Runnebaum IB, Karlan BY, et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002;7:553-66.
45. Makower D, Rozenblit A, Kaufman H, et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res 2003;2:693-702.
46. Kenzer MC, Randlev B, Valente N, et al. Intra-tumoral administration of ONYX-105 virus in breast cancer. Proc Am Soc Clin Oncol 2002;21:Abstract 1903.